Activation and activities of the p53 tumour suppressor protein

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1813-1823

  Balint E ^a   Vousden, K H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL REGENERATION; CLINICAL TRIAL; DNA REPAIR; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; STRESS;

EID: 0035555650     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2128     Document Type: Article

References (215)

1. Regulation of p53-mediated apoptosis and cell cycle arrest by steel factor
2. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
3. Maintenance of genomic integrity by p53: Complementary roles for activated and non-activated p53
4. Involvement of p53 in cell differentiation and development
5. Stabilization of wild-type by hypoxia-inducible factor 1α
6. waf-1/cip-1 and Mdm2 by etoposide: Etoposide inhibits the p53-Mdm2 autoregulatory loop
7. Regulation of p53 stability
8. Regulation of p53 function and stability by phosphorylation
9. Stress signals utilize multiple pathways to stabilize p53
10. Death receptors: Signaling and modulation
11. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines
12. p53 inhibits alpha 6 beta 4 integrin signaling by promoting the caspase 3-dependent cleavage of AKT/PKB
13. Mdm2 binds p73αwithout targeting degradation
14. Mdm-2 expression is induced by wild type p53 activity
15. ARF links the tumour suppressors RB and p53
16. Waf1/Cip1 expression
17. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
18. Cell surface trafficking of Fas: A rapid mechanism of p53 mediated apoptosis
19. The Werner syndrome protein contributes to induction of p53 by DNA damage
20. DNA damage induced p53 stabilization: No indication for an involvement of p53 phosphorylation
21. Apoptosis: Checkpoint at the mitochondrial frontier
22. Design of a synthetic Mdm-2 binding mini protein that activates the p53 responsein vivo
23. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
24. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2
25. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53
26. Radiation-induced cell cycle arrest compromised by p21 deficiency
27. Induction of the growth inhibitor IGF-binding protein 3 by p53
28. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein
29. Growth factor modulation of p53-mediated growth arrest versus apoptosis
30. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage
31. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
32. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
33. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression
34. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
35. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours
36. Transcriptional activation by p53 correlates with suppression of growth but not transformation
37. Excess β-catenin promotes accumulation of transcriptionally active p53
38. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
39. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
40. The p53-deficient mouse: A model for basic and applied cancer studies
41. WAF1, a potential mediator of p53 tumour suppression
42. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain
43. Epigenetic lesions causing genetic lesions in human cancer. Promoter hypermethylation of DNA reapir genes
44. Ubiquitin protein ligase activity of Mdm2: Differential RING finger requirements for ubiquitination and proteasomal targeting of Mdm2 and p53
45. PML is induced by oncogenicras and promotes premature senescence
46. Regulation of p53 activity in nuclear bodies by a specific PML isoform
47. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance
48. Pharmacological rescue of mutant p53 conformation and function
49. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
50. Functions of the MDM2 oncoprotein
51. JNK targets p53 ubiquitination and degradation in nonstressed cells
52. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo
53. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control
54. The MDM2 RING-finger domain is required to promote p53 nuclear export
55. Activation of p53 by conjugation to the ubiqutin-like protein SUMO-1
56. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal
57. Identification of a CK2 phosphorylation site in mdm2
58. p300/MDM2 complexes participate in MDM2-mediated p53 degradation
59. Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain
60. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation
61. The function of PML on p53-dependent apoptosis
62. p53 and human cancer; the first ten thousand mutations
63. The p21 CDK-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases
64. Mdm2 promotes the rapid degradation of p53
65. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains
66. 14-3-3σ is a p53-regulated inhibitor of G2/M progression
67. Activation of p53 in cervical carcinoma cells by small molecules
68. DNA damage-inducible activation of p53 by the checkpoint kinase Chk2
69. Genomic instability in Gadd45a-deficient mice
70. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
71. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
72. RB regulates the stability and the apoptotic function of p53 via MDM2
73. Regulation of the specific DNA binding function of p53
74. Role for the p53 homolog p73 in E2F1-induced apoptosis
75. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells
76. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2
77. MdmX protects p53 from Mdm2-mediated degradation
78. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breat cancers
79. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
80. Covalent and noncovalent modifiers of the p53 protein
81. Identification of redox/repair protein Ref-1 as a potent activator of p53
82. High mobility group protein-1 (HMG-1) is a unique activator of p53
83. A transactivation-deficient mouse model provides insights into Trp53 regulation and function
84. RING finger proteins: Mediators of ubiquitin ligase activity
85. Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53
86. Histone deacetylases specifically down-regulate p53-dependent gene activation
87. The Mdm2 oncoprotein interacts with the cell fate regulator Numb
88. ARF
89. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
90. Functional activation of p53 via phosphorylation following DNA damage by UV but not γ-irradiation
91. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
92. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DMA damage
93. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max
94. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
95. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
96. Regulation of p53 by hypoxia; dissociation of transcriptional repression and apoptosis from p53-dependent transactivation
97. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability
98. Regulation of p53 stability by Mdm2
99. Analysis of the degradation function of Mdm2
100. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODS
101. Regulation of p53 in response to DNA damage
102. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2
103. Cytokines inhibit p53-mediated apoptosis but not p53-mediated Gl arrest
104. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis
105. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
106. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress
107. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes
108. Identification of a cryptic nucleolar localization signal in MDM2
109. Apoptotic and growth-promoting activity of E2F modulated by MDM2
110. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
111. Genes involved in senescence and immortalization
112. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
113. Deacetylation of p53 modulates its effect on cell growth and apoptosis
114. p53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin
115. twist is a potential oncogene that inhibits apoptosis
116. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis
117. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias
118. Death signal-induced localization of p53 protein to the mitochondria
119. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes
120. Viral oncoproteins discriminate between p53 homolog p73
121. Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple western-phosphatase procedure
122. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53
123. Interactions between adenovirus proteins and the p53 pathway: The development of ONYX-015
124. Potential roles of p53 in nucleotide excision repair
125. Mechanisms of switching on p53: A role for covalent modifications
126. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
127. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
128. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
129. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
130. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
131. c-Jun and p53 activity is modulated by SUMO-1 modification
132. 14-3-3 proteins: Regulation of subcellular localization by molecular interference
133. PUMA, a novel pro-apopototic gene, is induced by p53
134. A ribonucleotide reductase gene is a transcriptional target of p53 and p73
135. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis
136. Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb
137. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
138. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
139. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress
140. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase
141. Amplification of a gene encoding a p53-associated protein in human sarcomas
142. MDM2 and MDMX bind and stabilize the p53-related protein p73
143. Wild-type human p53 and a temperature sensitive mutant induce Fas/APO-1 expression
144. Proteolysis by calpains: A possible contribution to degradation of p53
145. PML regulates p53 acetylation and premature senescence induced by oncogenic ras
146. p76 (MDM2) inhibits the ability of p90 (MDM2) to destabilize p53
147. E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways
148. Sequence-specific transcriptional activation is essential for growth suppression by p53
149. A model for p53-induced apoptosis
150. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
151. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells
152. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal
153. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation
154. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
155. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification
156. SUMO-1 modification activates the transcriptional response of p53
157. p53 tumor suppressor gene therapy for cancer
158. Characterization of structural p53 mutants which show selective defects in apoptosis, but not cell cycle arrest
159. Role of NF-kB in p53-mediated programmed cell death
160. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53
161. DNA damage activates p53 through a phosphorylation-acetylation cascade
162. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a caseine 1-like kinase. Effect on MDM2 binding
163. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
164. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
165. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells
166. Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein
167. Regulation of specific DNA binding by p53: Evidence for a role of O-glycosylation and charged residues at the carboxy-terminus
168. The ARF/p53 pathway
169. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
170. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
171. MDMX: A novel p53-binding protein with some functional properties of MDM2
172. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
173. Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells
174. c-Abl neutralizes the inhibitory effect of Mdm2 on p53
175. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
176. p53-mediated DNA repair responses to UV irradiation: Studies of mouse cells lacking p53, p21 and/or gadd45
177. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
178. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
179. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumini syndrome
180. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
181. ARF, participates in a regulatory feedback loop with p53 and MDM2
182. p53-inducible Wip1 phosphotase mediated a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation
183. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
184. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
185. MDM2 interacts with MDMX through their RING finger domains
186. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53
187. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element
188. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
189. Suppression of TNFα induced apoptosis by NF-kB
190. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase
191. Surfing the p53 network
192. p53: Death star
193. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanisms for inhibition of p53-dependent gene expression
194. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
195. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
196. Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation
197. GADD45 induction of a G2/M cell cycle checkpoint
198. Influence of p53 tumor suppressor protein in bias of DNA repair and apoptotic response in human cells
199. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
200. Nucleolar Arf sequesters Mdm2 and activates p53
201. Cooperative signals governing the ARF-Mdm2 interaction and nucleolar localization of the complex
202. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
203. NF-kappaB activation of p53. A potential mechanism for suppressing cell growth in response to stress
204. Differential regulation of the p21/WAF-1 and mdm2 genes after high dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene
205. The p53 mdm-2 autoregulatory feedback loop
206. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins
207. PUMA induces the rapid apoptosis of colorectal cancer cells
208. MDM2-dependent ubiquitnation of nuclear and cytoplasmic p53
209. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation
210. New insights into p53 regulation and gene therapy for cancer
211. MDM2 suppresses p73 function without promoting p73 degradation
212. UV but not gamma irradiation accelerates p53-induced apopotosis in teratocarcinoma cells by repressing MDM2 transcription
213. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Try diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition
214. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
215. A role for p53 in base excision repair